Sarepta Therapeutics, Inc.'s SEC filings document an operating biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under SRPT. Form 8-K reports furnish quarterly and annual financial results, product revenue disclosures for ELEVIDYS and PMO therapies, and clinical or regulatory updates for Duchenne muscular dystrophy treatments and siRNA pipeline programs.
Other filings cover proxy governance, executive compensation, equity-award plans and leadership-transition disclosures. Material-event reports also describe capital-structure actions, including exchange agreements for convertible senior notes, issuance of new convertible notes, common stock consideration and related indenture terms.
Sarepta Therapeutics, Inc. (SRPT), acting as an institutional investment manager, reported one Form 13F information-table entry with a total reported value of $0. The report is marked as covering all of the manager’s holdings and lists zero other included managers.
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, reported beneficial ownership of 1,386,343 shares of Sarepta Therapeutics, Inc. (SRPT) common stock each, equal to 1.31% of the class. The reported amount includes convertible notes representing 990,669 shares. Both entities reported shared voting and dispositive power over 1,386,343 shares.
State Street Corporation reported beneficial ownership of 7,412,275 shares of Sarepta Therapeutics, Inc. (SRPT) common stock, equal to 7% of the class. The report gives September 30, 2026 as the event date.
State Street reported shared voting power over 7,135,106 shares and shared dispositive power over 7,412,275 shares. It reported zero sole voting power and zero sole dispositive power. The report identifies six State Street investment adviser subsidiaries.
Sarepta Therapeutics, Inc. (SRPT) reported third-quarter 2026 revenue of $381.4 million, down 5% from $399.4 million a year earlier. Sarepta attributed the decline primarily to lower ELEVIDYS sales under the updated ambulatory-patient label, partly offset by a $31.4 million increase in contract manufacturing revenue from higher ELEVIDYS supply delivered to Roche. Net product revenue was $323.8 million, including $240.3 million from PMO products and $83.5 million from ELEVIDYS. GAAP operating loss narrowed to $9.0 million from $103.4 million; non-GAAP operating income was $22.9 million versus a $35.7 million loss, and GAAP net loss narrowed to $28.5 million from $50.6 million.
Full-year 2026 total net product revenue guidance is $1.25 billion to $1.3 billion, with the low end raised by $50.0 million. Combined non-GAAP R&D and SG&A expense guidance is $800 million to $825 million, with the high end lowered by $25.0 million. Cash, cash equivalents, restricted cash and investments totaled $998.7 million as of September 30, 2026. Multiple ascending dose data for SRP-1003 in DM1 and SRP-1001 in FSHD are expected in the fourth quarter of 2026; Sarepta is preparing for potential Phase 3 development, including clinical supply manufacturing. Cost of sales included a $62.0 million take-or-pay charge related to non-cancelable manufacturing obligations for inventory Sarepta elected not to manufacture.
Sarepta Therapeutics, Inc. (SRPT) reported third-quarter 2026 revenue of $381.4 million and a net loss of $28.5 million, versus $399.4 million in revenue and a $50.6 million net loss a year earlier. Nine-month revenue was $1,513.4 million versus $1,755.3 million; net income was $297.6 million versus a $301.2 million net loss.
Nine-month operating cash flow was $54.4 million, versus $336.7 million used in 2025. Cash, cash equivalents, restricted cash and investments totaled $998.7 million as of September 30, 2026. Sarepta said it believes its cash, cash equivalents and investments, future operating inflows and Revolving Credit Facility availability are sufficient for its current operational plan for at least twelve months.
Shipments of ELEVIDYS to non-ambulatory U.S. patients were suspended in June 2025. In November 2025, Sarepta disclosed a boxed warning for acute liver injury and acute liver failure and stated that the non-ambulatory population had been removed from the Indication and Usage section. The company is studying sirolimus with ELEVIDYS and plans to discuss results and a potential pathway with the FDA; resumption depends partly on FDA analysis and alignment on label revision.
On September 23, 2026, Sarepta Therapeutics, Inc. entered into a settlement agreement with REGENXBIO Inc., the Trustees of the University of Pennsylvania, Catalent, Inc. and its subsidiary Sarepta Therapeutics Three, LLC, regarding the resolution of pending patent infringement litigations and an appeal from inter partes review proceedings.
Sarepta will pay REGENXBIO a lump sum of $39.0 million within ten days of the agreement’s effective date. Sarepta recorded a $39.0 million litigation contingency charge related to the anticipated settlement for the three and six months ended June 30, 2026. REGENXBIO and the Trustees released Sarepta, Catalent and their affiliates from specified past patent claims concerning Sarepta gene therapy products using an AAVrh74-based capsid, including ELEVIDYS, and agreed not to sue over qualifying claims. REGENXBIO also agreed not to sue over certain claims concerning patents or applications covering the existing form of ELEVIDYS or the AAVrh74 capsid sequence. The agreement provides for dismissal, withdrawal or other disposal of the litigations with prejudice, and each party will bear its own related costs, expenses and attorneys’ fees.
Sarepta Therapeutics, Inc. (SRPT) reported that its Chief Financial Officer, Ryan Ho-Yan Wong, had 13,272 shares of common stock withheld on September 4, 2026 to pay tax liabilities tied to the vesting of restricted stock units granted on September 3, 2025. After this withholding, he directly holds 121,792 shares of Sarepta common stock. No transactions were made under a Rule 10b5-1 trading plan.
Sarepta Therapeutics, Inc. (SRPT) reported that Chief Operating Officer Ian Michael Estepan had 24,799 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units granted on September 3, 2025. The shares were valued at $22.22 per share for this withholding transaction, and Estepan now directly holds 177,184 shares of Sarepta common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Sarepta Therapeutics, Inc. (SRPT) reported that EVP, General Counsel Cristin Rothfuss had 22,025 shares of common stock withheld on September 4, 2026 to pay tax withholding obligations arising from the vesting of restricted stock units granted on September 3, 2025. After this tax-related disposition, Rothfuss directly holds 115,519 shares of Sarepta common stock. No Rule 10b5-1 trading plan is reported.
Sarepta Therapeutics, Inc. (SRPT) reported that Louise Rodino-Klapac, President, R&D and Tech Ops, had 21,423 shares of common stock withheld on September 4, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on September 3, 2025. This was a disposition of shares for tax payment rather than an open‑market sale, and no Rule 10b5-1 trading plan is reported. After this withholding, she directly held 203,900 shares of Sarepta common stock.